Equities Analysts Offer Predictions for Sarepta Therapeutics Inc’s Q2 2018 Earnings (SRPT)

Sarepta Therapeutics Inc (NASDAQ:SRPT) – Equities research analysts at Leerink Swann issued their Q2 2018 EPS estimates for Sarepta Therapeutics in a report released on Wednesday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings of ($0.34) per share for the quarter. Leerink Swann has a “Outperform” rating and a $66.00 price objective on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ Q3 2018 earnings at ($0.25) EPS and Q4 2018 earnings at ($0.19) EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The company had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same quarter last year, the firm earned ($0.95) EPS.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Oppenheimer reissued a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Robert W. Baird reissued an “outperform” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Finally, UBS Group reissued an “outperform” rating and issued a $56.51 price target (down previously from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $63.88.

Sarepta Therapeutics (NASDAQ SRPT) traded down $2.60 during mid-day trading on Friday, hitting $55.21. 1,046,693 shares of the company traded hands, compared to its average volume of 2,139,100. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $59.95. The company has a market cap of $3,590.00, a price-to-earnings ratio of -27.07 and a beta of 1.37.

A number of institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. raised its holdings in Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Advisor Group Inc. raised its holdings in Sarepta Therapeutics by 3.2% in the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after buying an additional 326 shares during the last quarter. Legal & General Group Plc raised its holdings in Sarepta Therapeutics by 3.9% in the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after buying an additional 663 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Sarepta Therapeutics by 0.8% in the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after buying an additional 818 shares during the last quarter. Finally, C WorldWide Group Holding A S raised its holdings in Sarepta Therapeutics by 0.8% in the third quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock worth $5,555,000 after buying an additional 941 shares during the last quarter. 82.02% of the stock is owned by institutional investors and hedge funds.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Offer Predictions for Sarepta Therapeutics Inc’s Q2 2018 Earnings (SRPT)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/05/equities-analysts-offer-predictions-for-sarepta-therapeutics-incs-q2-2018-earnings-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply